130 related articles for article (PubMed ID: 9434462)
21. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Mori Y; Kitahara Y; Miura K; Tajima N
Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195
[TBL] [Abstract][Full Text] [Related]
22. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
23. [Type 2 diabetes. Regulating insulin according to need].
MMW Fortschr Med; 2001 Oct; 143(42):62. PubMed ID: 11697294
[No Abstract] [Full Text] [Related]
24. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
25. Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Blackburn GL
Health News; 2004 Aug; 10(8):4-5. PubMed ID: 15551454
[No Abstract] [Full Text] [Related]
26. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine an optimal indication for nateglinide.
Mori Y; Ishii H; Hikita M; Tajima N
Adv Ther; 2003; 20(6):352-9. PubMed ID: 15058753
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
29. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
30. Quo vadis nateglinide? Ten-year perspective.
Grunberger G
Expert Opin Pharmacother; 2011 Sep; 12(13):2097-106. PubMed ID: 21801074
[TBL] [Abstract][Full Text] [Related]
31. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
32. [Metformin--its regimen and effects].
Shiba T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():382-8. PubMed ID: 12387022
[No Abstract] [Full Text] [Related]
33. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
34. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Mori Y; Mamori S; Tajima N
Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
[TBL] [Abstract][Full Text] [Related]
35. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
36. Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Li C; Xia J; Zhang G; Wang S; Wang L
Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841
[TBL] [Abstract][Full Text] [Related]
37. [Therapy of type 2 diabetes. Effective control of postprandial glucose surges].
MMW Fortschr Med; 2001 Jul; 143(28-29):56-7. PubMed ID: 11499153
[No Abstract] [Full Text] [Related]
38. [Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
MMW Fortschr Med; 2002 May; 144(21):58. PubMed ID: 12134432
[No Abstract] [Full Text] [Related]
39. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
40. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]